Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: A multicenter study in the Czech Republic

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F20%3A43920276" target="_blank" >RIV/00216208:11120/20:43920276 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/20:10412554 RIV/00064211:_____/20:W0000016

Výsledek na webu

<a href="https://doi.org/10.1111/jdv.16771" target="_blank" >https://doi.org/10.1111/jdv.16771</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/jdv.16771" target="_blank" >10.1111/jdv.16771</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: A multicenter study in the Czech Republic

Popis výsledku v původním jazyce

Patient concerns about the possible increased susceptibility to coronavirus disease 19 (COVID-19) infection or a more severe course of the disease when treated with immunosuppressive therapy may lead to lower treatment compliance. Treatment safety concerns were significantly more commonin the biologics-treated patients, where 40.7% either agreed/strongly agreed of having experienced an increased risk of COVID-19 infection as compared to 21.3% in the conventional systemic group (P&lt;0.01) and 10.9% in the topical therapy group (P&lt;0.00001). This study has limitations. Patient anxiety is affected by the severity of psoriasis, but in our study, patients on biologics hadrecently a milder case of the disease than patients in the other groups. It is also possible that the relationship between psoriasis treatment and anxiety could be indirect (e.g. due to unmeasured confounding) and not a direct consequence of the COVID-19 pandemic.In conclusion, the overall compliance of biologic treatment of patients with psoriasis during the COVID-19 pandemic lock-down was extremely good despite expressing anxiety and more frequent concerns about the safety of their treatment compared to patients on other therapies.

Název v anglickém jazyce

Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: A multicenter study in the Czech Republic

Popis výsledku anglicky

Patient concerns about the possible increased susceptibility to coronavirus disease 19 (COVID-19) infection or a more severe course of the disease when treated with immunosuppressive therapy may lead to lower treatment compliance. Treatment safety concerns were significantly more commonin the biologics-treated patients, where 40.7% either agreed/strongly agreed of having experienced an increased risk of COVID-19 infection as compared to 21.3% in the conventional systemic group (P&lt;0.01) and 10.9% in the topical therapy group (P&lt;0.00001). This study has limitations. Patient anxiety is affected by the severity of psoriasis, but in our study, patients on biologics hadrecently a milder case of the disease than patients in the other groups. It is also possible that the relationship between psoriasis treatment and anxiety could be indirect (e.g. due to unmeasured confounding) and not a direct consequence of the COVID-19 pandemic.In conclusion, the overall compliance of biologic treatment of patients with psoriasis during the COVID-19 pandemic lock-down was extremely good despite expressing anxiety and more frequent concerns about the safety of their treatment compared to patients on other therapies.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of the European Academy of Dermatology and Venereology

ISSN

0926-9959

e-ISSN

—

Svazek periodika

34

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

3

Strana od-do

"e682"-"e684"

Kód UT WoS článku

000546564300001

EID výsledku v databázi Scopus

2-s2.0-85087730121